Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses PLSE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PLSE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul LaViolette | $708,523 | $0 | $0 | $6,717,960 | $0 | $0 | $1,416 | $7,427,899 |
| Chief Executive Officer and Co-Chairman | ||||||||
| Jon Skinner | 366,667 | 56,000 | 0 | 2,419,035 | 0 | 0 | 1,298 | 2,843,000 |
| Chief Financial Officer | ||||||||
| Darrin Uecker | 540,312 | 328,161 | 0 | 0 | 0 | 0 | 1,416 | 869,889 |
| Chief Technology Officer and Director | ||||||||
| Kevin Danahy | 525,000 | 328,161 | 0 | 0 | 0 | 0 | 1,416 | 854,577 |
| Former Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul LaViolette | $7,427,899 | — | — | — |
| Jon Skinner | 2,843,000 | — | — | — |
| Darrin Uecker | 869,889 | — | — | — |
| Kevin Danahy | 854,577 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul LaViolette | Option | 125,000 | 15.65 | — |
| Paul LaViolette | Option | 31,250 | 15.65 | — |
| Paul LaViolette | Option | 5,425 | 18.43 | — |
| Paul LaViolette | Option | 107,075 | 18.43 | — |
| Paul LaViolette | Option | 332,075 | 18.43 | — |
| Paul LaViolette | Option | 600,000 | 18.43 | — |
| Paul LaViolette | Option | 450,000 | 18.43 | — |
| Kevin Danahy | Option | 25,000 | 6.41 | — |
| Kevin Danahy | Option | 112,500 | 1.53 | — |
| Kevin Danahy | Option | 500,000 | 6.44 | — |
| Kevin Danahy | Option | 200,000 | 7.08 | — |
| Kevin Danahy | Option | 460,000 | 4.38 | — |
| Darrin Uecker | Option | 500,000 | 6.44 | — |
| Darrin Uecker | Option | 200,000 | 7.08 | — |
| Darrin Uecker | Option | 330,000 | 4.38 | — |
| Jon Skinner | Option | 19,616 | 20.93 | — |
| Jon Skinner | Option | 130,384 | 20.93 | — |
| Jon Skinner | Option | 150,000 | 20.93 | — |
We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-12-09 | 52,270,567 | 907,916 | 11,364 | 98.29% | Passed |
| 2022 | 2022-05-19 | 18,144,288 | 318,393 | 39,944 | 98.28% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-12-09 | 98.29%a |
| 2022 | 2022-05-19 | 98.28%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 26,000 / 15,300 / 11,000 |
| Stock ownership guideline | — |
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Pulse Biosciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Pulse Biosciences.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Option | 2025 | John Rademacher | $1,000,000 | $6,500,050 | $0 | $1,665,000 | $9,266,330 |
| 2 | Pulse Biosciences | 2025 | Paul LaViolette | 708,523 | 0 | 6,717,960 | 0 | 7,427,899 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Pulse Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Option | 111% | PSU 60 · RSU 40 | No | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Paul LaViolette | DEF 14A | 2026-05-11 | 0001437749-26-016006 | Section “Summary Compensation Table” · page 28. As printed: 7,427,899. Filing ↗machine: r1 · c21 · span 428112–428121 |
| 2 | Section 01, Jon Skinner | DEF 14A | 2026-05-11 | 0001437749-26-016006 | Section “Summary Compensation Table” · page 28. As printed: 2,843,000. Filing ↗machine: r5 · c21 · span 441306–441315 |
| 3 | Section 01, Darrin Uecker | DEF 14A | 2026-05-11 | 0001437749-26-016006 | Section “Summary Compensation Table” · page 28. As printed: 869,889. Filing ↗machine: r9 · c21 · span 454353–454360 |
| 4 | Section 01, Kevin Danahy | DEF 14A | 2026-05-11 | 0001437749-26-016006 | Section “Summary Compensation Table” · page 28. As printed: 854,577. Filing ↗machine: r13 · c21 · span 467676–467683 |
| 5 | Section 06, 2025 vote | Form 8-K | 2025-12-12 | 0001437749-25-037727 | Item 5.07 · say-on-pay result. As reported: 98.29% (votes for as printed: 52,270,567). Filing ↗ |
| 6 | Section 06, 2022 vote | Form 8-K | 2022-05-23 | 0001625101-22-000041 | Item 5.07 · say-on-pay result. As reported: 98.28% (votes for as printed: 18,144,288). Filing ↗ |
| 7 | Option, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013825 | CEO total compensation as printed in Option's own proxy. As printed: 9,266,330. Filing ↗machine: r2 · c25 · span 1114074–1114083 |
| 8 | Pulse Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-05-11 | 0001437749-26-016006 | CEO total compensation as printed in Pulse Biosciences's own proxy. As printed: 7,427,899. Filing ↗machine: r1 · c21 · span 428112–428121 |
| 9 | Section 10a, Option reciprocity | DEF 14A | — | 0001140361-26-013825 | Option's most recent proxy was read; its disclosed peer group does not include Pulse Biosciences. Filing ↗ |